Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
|
SCHEDULE 13G
|
||
| |
Under the Securities Exchange Act of 1934
|
|
|
(Amendment No. 2)*
|
|
Eledon Pharmaceuticals, Inc.
|
||
|
(Name of Issuer)
|
|
Common Stock
|
||
|
(Title of Class of Securities)
|
|
28617K901
|
||
|
(CUSIP Number)
|
|
December 31, 2022
|
||
|
(Date of Event which Requires Filing of this Statement)
|
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
[ ] Rule 13d-1(b)
[x] Rule 13d-1(c)
[ ] Rule 13d-1(d)
___________________________________
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934
(“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
|
1
|
Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only)
Cormorant Global Healthcare Master Fund, LP
|
|
2
|
Check the Appropriate Box if a Member of a Group (See Instructions)
|
|
(a) [ ]
|
|
|
(b) [x]
|
|
|
3
|
SEC Use Only
|
|
4
|
Citizenship or Place of Organization.
Cayman Islands
|
|
Number
of Shares
Beneficially
Owned by
Each
Reporting
Person With
|
5 Sole Voting Power
0 shares
|
|
6 Shared Voting Power
1,391,663 shares (#)
Refer to Item 4 below.
|
|
|
7 Sole Dispositive Power
0 shares
|
|
|
8 Shared Dispositive Power
1,391,663 shares (#)
Refer to Item 4 below.
|
|
9
|
Aggregate Amount Beneficially Owned by Each Reporting Person
1,391,663 shares (#)
Refer to Item 4 below.
|
|
|
10
|
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
[ ] N/A
|
|
|
11
|
Percent of Class Represented by Amount in Row (9)*
9.99% (#)
Refer to Item 4 below.
|
|
|
12
|
Type of Reporting Person (See Instructions)
PN (Partnership)
|
(#) Includes 173,781 shares of Common Stock issuable upon the conversion of shares of Series X1 Convertible Preferred Stock held by the Reporting Persons. See Item 4 below.
|
1
|
Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only)
Cormorant Global Healthcare GP, LLC
|
|
2
|
Check the Appropriate Box if a Member of a Group (See Instructions)
|
|
(a) [ ]
|
|
|
(b) [x]
|
|
|
3
|
SEC Use Only
|
|
4
|
Citizenship or Place of Organization.
Delaware
|
|
Number
of Shares
Beneficially
Owned by
Each
Reporting
Person With
|
5 Sole Voting Power
0 shares
|
|
6 Shared Voting Power
1,391,663 shares (#)
Refer to Item 4 below.
|
|
|
7 Sole Dispositive Power
0 shares
|
|
|
8 Shared Dispositive Power
1,391,663 shares (#)
Refer to Item 4 below.
|
|
9
|
Aggregate Amount Beneficially Owned by Each Reporting Person
1,391,663 shares (#)
Refer to Item 4 below.
|
|
|
10
|
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
[ ] N/A
|
|
|
11
|
Percent of Class Represented by Amount in Row (9)*
9.99% (#)
Refer to Item 4 below.
|
|
|
12
|
Type of Reporting Person (See Instructions)
OO (Limited Liability Company)
|
(#) Includes 173,781 shares of Common Stock issuable upon the conversion of shares of Series X1 Convertible Preferred Stock held by the Reporting Persons. See Item 4 below.
|
1
|
Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only)
Cormorant Asset Management, LP
|
|
2
|
Check the Appropriate Box if a Member of a Group (See Instructions)
|
|
(a) [ ]
|
|
|
(b) [x]
|
|
|
3
|
SEC Use Only
|
|
4
|
Citizenship or Place of Organization.
Delaware
|
|
Number
of Shares
Beneficially
Owned by
Each
Reporting
Person With
|
5 Sole Voting Power
0 shares
|
|
6 Shared Voting Power
1,391,663 shares (#)
Refer to Item 4 below.
|
|
|
7 Sole Dispositive Power
0 shares
|
|
|
8 Shared Dispositive Power
1,391,663 shares (#)
Refer to Item 4 below.
|
|
9
|
Aggregate Amount Beneficially Owned by Each Reporting Person
1,391,663 shares (#)
Refer to Item 4 below.
|
|
|
10
|
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
[ ] N/A
|
|
|
11
|
Percent of Class Represented by Amount in Row (9)*
9.99% (#)
Refer to Item 4 below.
|
|
|
12
|
Type of Reporting Person (See Instructions)
PN (Partnership)
|
(#) Includes 173,781 shares of Common Stock issuable upon the conversion of shares of Series X1 Convertible Preferred Stock held by the Reporting Persons. See Item 4 below.
|
1
|
Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only)
Bihua Chen
|
|
2
|
Check the Appropriate Box if a Member of a Group (See Instructions)
|
|
(a) [ ]
|
|
|
(b) [x]
|
|
|
3
|
SEC Use Only
|
|
4
|
Citizenship or Place of Organization.
United States
|
|
Number
of Shares
Beneficially
Owned by
Each
Reporting
Person With
|
5 Sole Voting Power
0 shares
|
|
6 Shared Voting Power
1,391,663 shares (#)
Refer to Item 4 below.
|
|
|
7 Sole Dispositive Power
0 shares
|
|
|
8 Shared Dispositive Power
1,391,663 shares (#)
Refer to Item 4 below.
|
|
9
|
Aggregate Amount Beneficially Owned by Each Reporting Person
1,391,663 shares (#)
Refer to Item 4 below.
|
|
|
10
|
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
[ ] N/A
|
|
|
11
|
Percent of Class Represented by Amount in Row (9)*
9.99% (#)
Refer to Item 4 below.
|
|
|
12
|
Type of Reporting Person (See Instructions)
IN (Individual)
|
(#) Includes 173,781 shares of Common Stock issuable upon the conversion of shares of Series X1 Convertible Preferred Stock held by the Reporting Persons. See Item 4 below.
Item 1.
|
(a)
|
Name of Issuer
|
|
Eledon Pharmaceuticals, Inc.
|
|
|
(b)
|
Address of Issuer’s Principal Executive Offices
|
|
19900 MacArthur Blvd., Suite 550 Irvine, CA 92612
|
Item 2.
|
(a)
|
Name of Person Filing
|
|
Cormorant Global Healthcare Master Fund, LP
Cormorant Global Healthcare GP, LLC Cormorant Asset Management, LP
Bihua Chen |
|
|
(b)
|
Address of Principal Business Office or, if none, Residence
|
|
200 Clarendon Street, 52nd Floor
Boston, MA 02116
|
|
|
(c)
|
Citizenship
|
|
Cormorant Global Healthcare Master Fund, LP - Cayman Islands
Cormorant Global Healthcare GP, LLC - Delaware Cormorant Asset Management, LP - Delaware
Bihua Chen - United States |
|
|
(d)
|
Title of Class of Securities
|
|
Common Stock
|
|
|
(e)
|
CUSIP Number
|
|
28617K901
|
| Item 3. |
If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
|
|
(a)
|
[ ]
|
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
|
|
(b)
|
[ ]
|
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
|
|
(c)
|
[ ]
|
Insurance Company as defined in Section 3(a)(19) of the Act
|
|
(d)
|
[ ]
|
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
|
|
(e)
|
[ ]
|
An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
|
|
(f)
|
[ ]
|
An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
|
|
(g)
|
[ ]
|
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
|
|
(h)
|
[ ]
|
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
|
|
(i)
|
[ ]
|
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
|
|
(j)
|
[ ]
|
A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);
|
|
(k)
|
[ ]
|
Group, in accordance with §240.13d-1(b)(1)(ii)(K).
|
| Item 4. |
Ownership***#
|
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
|
(a)
|
Amount Beneficially Owned***#
|
|
The information set forth in Rows 5 through 11 on the cover page for each Reporting Person is hereby incorporated by reference into this Item 4(a) for each such Reporting Person.
|
|
|
(b)
|
Percent of Class
|
|
The information set forth in Rows 5 through 11 on the cover page for each Reporting Person is hereby incorporated by reference into this Item 4(b) for each such Reporting Person.
|
|
(c)
|
Number of shares as to which such person has:
|
|
|
(i)
|
sole power to vote or to direct the vote
|
|
|
|
||
|
(ii)
|
shared power to vote or to direct the vote
|
|
|
|
||
|
(iii)
|
sole power to dispose or to direct the disposition of
|
|
|
(iv)
|
shared power to dispose or to direct the disposition of
|
|
|
|
||
|
The information set forth in Rows 5 through 11 on the cover page for each Reporting Person is hereby incorporated by reference into this Item 4(c) for each such Reporting Person.
|
||
*** Shares reported herein for Cormorant Asset Management, LP represent shares which are beneficially owned by Cormorant Global Healthcare Master
Fund, LP (the “Master Fund”) as reported herein. Cormorant Global Healthcare GP, LLC serves as the general partner of the Master Fund. Cormorant Asset Management, LP serves as the investment manager to the Master Fund. Bihua Chen serves as the managing
member of Cormorant Global Healthcare GP, LLC and the general partner of Cormorant Asset Management, LP. Each of the Reporting Persons disclaims beneficial ownershi
p of the shares reported herein except to the extent of its or his pecuniary interest
therein.
(#) The Reporting Persons' holdings reported herein include shares of common stock of the Issuer (“Common Stock”) issuable upon the conversion
of shares of Series X1 Preferred stock of the Issuer (“Preferred Stock”) owned by the Master Fund. Under its terms, the Preferred Stock may be converted to Common Stock only to the extent that such conversion would not cause the holder thereof,
together with its affiliates and any other person or entity acting as a group, to beneficially own in excess of 9.99% (subject to adjustment in accordance with the terms of the Preferred Stock) of the shares of Common Stock then outstanding. The
Master Fund owns 1,217,882 shares of Common Stock and may receive up to 537,000 additional shares of Common Stock upon the conversion of Preferred Stock, subject to the limitation on conversion.
The percentages reported herein with respect to the Reporting Persons' holdings are based upon a statement in the Issuer's Quarterly Report on Form 10-Q for the quarterly
period ended September 30, 2022, as filed with the Securities and Exchange Commission on November 14, 2022, that there were 13,756,788 shares of Common Stock outstanding as of November 10, 2022. If not for such limitation on conversion, the Reporting
Persons would beneficially own in excess of 9.99% of the Issuer's outstanding shares of Common Stock.
| Item 5. |
Ownership of Five Percent or Less of a Class
|
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of
more than five percent of the class of securities, check the following [ ].
| Item 6. |
Ownership of More than Five Percent on Behalf of Another Person
|
Not applicable.
| Item 7. |
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
|
Not applicable.
| Item 8. |
Identification and Classification of Members of the Group
|
Not applicable.
| Item 9. |
Notice of Dissolution of Group
|
Not applicable.
| Item 10. |
Certification
|
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or
with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
| Exhibits |
Exhibit
|
| 99.1 |
Joint Filing Agreement by and among the Reporting Persons, incorporated by reference to Exhibit 99.1 to the Schedule
13G filed by the Reporting Persons with the Securities and Exchange Commission on January 4, 2021.
|
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true,
complete and correct.
February 14, 2023
CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP
By: Cormorant Global Healthcare GP, LLC
its General Partner
By: /s/ Bihua Chen
Bihua Chen, Managing Member
CORMORANT GLOBAL HEALTHCARE GP, LLC
By: /s/ Bihua Chen
Bihua Chen, Managing Member
CORMORANT ASSET MANAGEMENT, LP
By: Cormorant Asset Management GP, LLC
its General Partner
By: /s/ Bihua Chen
Bihua Chen, Managing Member
/s/ Bihua Chen
Bihua Chen